Assignee
REMEGEN CO LTD
CN·8 granted patents·19 pending applications·0 citations·filing 2019–2024
Top patents by PatentIndex Score
27 records- 0168US2025145731A1Linker for antibody-drug conjugates and its useREMEGEN CO LTD·Filed 2024·Application pending·0 cites
- 0266US12195552B2Linker for antibody-drug conjugates and its useREMEGEN CO LTD·Filed 2019·Granted Jan 14, 2025·0 cites·1 claims
- 0366US2024207424A1Use of her2-targeting antibody-drug conjugate in treatment of her2-low expressing breast cancerREMEGEN CO LTD·Filed 2023·Application pending·0 cites
- 0466US2025250313A1Il-15 agonists for cancerREMEGEN CO LTD·Filed 2024·Application pending·0 cites
- 0564US2026098077A1Method for treating membranous nephropathy with taci-fc fusion proteinREMEGEN CO LTD·Filed 2023·Application pending·0 cites
- 0663US2024207431A1Use of antibody-drug conjugate in combination with immune checkpoint inhibitor in treatment of urothelial cancerREMEGEN CO LTD·Filed 2023·Application pending·0 cites
- 0762US2024025947A1Preparation and purification process of monomethyl auristain e compoundREMEGEN CO LTD·Filed 2023·Application pending·0 cites
- 0861US12372504B2Method for detecting TCEP content in ADC by LC-MS/MSREMEGEN CO LTD·Filed 2022·Granted Jul 29, 2025·0 cites·12 claims
- 0961US2025186548A1Method for treating myasthenia gravis with taci-fc fusion proteinREMEGEN CO LTD·Filed 2023·Application pending·0 cites
- 1060US11629180B2Bifunctional angiogenesis inhibitor and use thereofREMEGEN CO LTD·Filed 2019·Granted Apr 18, 2023·0 cites·21 claims
- 1160US2024033368A1Preparation and purification method of antibody drug conjugate intermediateREMEGEN CO LTD·Filed 2023·Application pending·0 cites
- 1259US12577320B2Anti-Claudin 18.2 antibody and antibody-drug conjugate thereofREMEGEN CO LTD·Filed 2022·Granted Mar 17, 2026·0 cites·32 claims
- 1359US2024148894A1Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancerREMEGEN CO LTD·Filed 2023·Application pending·0 cites
- 1458US2024018212A1Method for treating sjogren's syndrome using taci-fc fusion proteinREMEGEN CO LTD·Filed 2022·Application pending·0 cites
- 1558US2024002468A1Method for treating iga nephropathy with taci-fc fusion proteinREMEGEN CO LTD·Filed 2022·Application pending·0 cites
- 1657US12528870B2Anti-c-Met antibody-drug conjugate and applications thereofREMEGEN CO LTD·Filed 2021·Granted Jan 20, 2026·0 cites·33 claims
- 1757US2026098866A1Taci antibody and use thereofREMEGEN CO LTD·Filed 2023·Application pending·0 cites
- 1856US2025352617A1Taci-fc fusion protein liquid pharmaceutical preparationREMEGEN CO LTD·Filed 2023·Application pending·0 cites
- 1955US2025074872A1Method for preparing and purifying monomethyl auristatin e intermediateREMEGEN CO LTD·Filed 2023·Application pending·0 cites
- 2054US12510522B2Method for detecting DTPA content in ADC by LC-MS/MSREMEGEN CO LTD·Filed 2022·Granted Dec 30, 2025·0 cites·12 claims
- 2154US2022204626A1Bispecific fusion protein and application thereofREMEGEN CO LTD·Filed 2021·Application pending·0 cites
- 2253US2022002381A1Taci-fc fusion proteins and uses thereofREMEGEN CO LTD·Filed 2019·Application pending·0 cites
- 2353US2024189341A1Pharmaceutical combination and use thereofREMEGEN CO LTD·Filed 2022·Application pending·0 cites
- 2450US12404333B2Anti PD-L1 antibody and use thereofREMEGEN CO LTD·Filed 2020·Granted Sep 2, 2025·0 cites·12 claims
- 2546US12514821B2Pharmaceutical TACI-Fc fusion protein formulationREMEGEN CO LTD·Filed 2020·Granted Jan 6, 2026·0 cites·19 claims
- 2644US2021238305A1Antibody for her2 concomitant diagnosis immunohistochemical detection and application thereofREMEGEN CO LTD·Filed 2020·Application pending·0 cites
- 2739US2021154314A1Pharmaceutical formulations of her2 antibody-drug conjugateREMEGEN CO LTD·Filed 2020·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →